文献速递复苏、休克与脓毒症呼吸衰竭与机械通气

持续复苏中胸外按压同步通气时声门上气道装置的效果:一项前瞻性随机交叉尸体研究

Efficacy of supraglottic airway devices in chest compression synchronized ventilation during continuous resuscitation: a prospective randomized cross-over cadaver study.
PubMed 文献 · Resuscitation · 2025-09-02
一句话结论在持续胸外按压下实施按压同步通气(CCSV)时,使用声门上气道装置(SGA)比气管插管更难达到目标气道压、潮气量更低且漏气更多,因此无论使用何种气道装置都需警惕CCSV失败。

该前瞻性随机交叉尸体研究纳入11具成人Thiel防腐尸体,先用气管插管(TI)建立肺通气,再在持续胸外按压下随机顺序使用各型SGA(Ambu®AuraGain™、LTS-D®、I-GEL®)与TI,以气道压40 mbar、PEEP 3 mbar、呼吸频率与按压频率同步的方式实施CCSV。主要终点为达到pCCSV 40±3 mbar。结果显示,与SGA相比,TI达到目标气道压的机会更高(OR 1.87,95%CI 0.91–3.83,P=0.0864,未达统计学显著)、pCCSV更高、呼气潮气量更高、漏气量更低。各SGA之间,Ambu®AuraGain™的pCCSV低于I-GEL®和LTS-D®。作者结论:SGA与达标可能性更低、潮气量更低、漏气更多相关;不论何种气道装置均可能发生CCSV失败,强调需密切监测呼吸。

要点

  • 在持续胸外按压下实施CCSV时,TI达到pCCSV 40±3 mbar目标范围的机会高于SGA(OR 1.87,95%CI 0.91–3.83,P=0.0864,未达统计学显著)。
  • 与SGA相比,TI的pCCSV更高(回归系数2.99 mbar,95%CI 1.63–4.35,p<0.0001),呼气潮气量更高(回归系数42.42 ml,95%CI 32.07–52.27,p<0.0001),漏气量更低(回归系数−55.03%,95%CI −62.92至−47.15,p<0.0001)。
  • 各SGA之间,Ambu®AuraGain™的pCCSV低于I-GEL®(回归系数−2.58 mbar,95%CI −4.04至−1.13,p=0.0006)和LTS-D®(回归系数−1.73 mbar,95%CI −3.18至−0.27,p=0.0204);LTS-D®与I-GEL®之间无显著差异(回归系数−0.86 mbar,95%CI −2.30至0.59,p=0.2434)。
  • 11具尸体中有3具(27%)仅能用TI通气,2具(18%)用包括TI在内的任何装置均无法充分通气,2具(18%)用所有类型气道装置均成功通气。
  • 作者结论:无论使用何种气道装置,CCSV均可能失败,强调需对呼吸进行密切监测。

适用人群与场景

  • 研究对象为成人Thiel防腐尸体模型,用于评估持续胸外按压下CCSV的通气效果;原文未列出人体患者的纳入或排除标准。

诊断标准与关键阈值

  • CCSV设置:CCSV压力(pCCSV)=40 mbar,PEEP=3 mbar,呼吸频率与胸外按压频率同步。
  • 主要终点为达到pCCSV=40±3 mbar;次要终点包括pCCSV、呼气潮气量(Vte)1 ml/kgBW和漏气量(Vleak)。

处置流程与药物剂量

  • 第一步:先用气管插管(TI)对尸体肺进行初始招募通气。
  • 第二步:在持续胸外按压下,按随机顺序应用各型SGA(喉罩Ambu®AuraGain™、喉管LTS-D®、i-gel喉罩I-GEL®)与TI,并以pCCSV=40 mbar、PEEP=3 mbar、呼吸频率与按压频率同步实施CCSV。
  • 第三步:以pCCSV=40±3 mbar为达标标准评估通气,同时记录pCCSV、Vte(1 ml/kgBW)与Vleak。

研究设计与关键结果

  • 研究类型:前瞻性随机交叉尸体研究;样本量11具成人Thiel防腐尸体。
  • 干预与对照:在持续胸外按压下按随机顺序使用TI与各型SGA(Ambu®AuraGain™、LTS-D®、I-GEL®)实施CCSV,pCCSV目标为40±3 mbar。
  • 主要终点:TI达到pCCSV目标范围的机会高于SGA(OR 1.87,95%CI 0.91–3.83,P=0.0864)。
  • 关键次要终点:TI较SGA的pCCSV更高(回归系数2.99 mbar,95%CI 1.63–4.35,p<0.0001),Vte更高(回归系数42.42 ml,95%CI 32.07–52.27,p<0.0001),Vleak更低(回归系数−55.03%,95%CI −62.92至−47.15,p<0.0001)。
  • SGA之间:Ambu®AuraGain™的pCCSV低于I-GEL®(回归系数−2.58 mbar,95%CI −4.04至−1.13,p=0.0006)和LTS-D®(回归系数−1.73 mbar,95%CI −3.18至−0.27,p=0.0204);LTS-D®与I-GEL®之间差异未达统计学显著(回归系数−0.86 mbar,95%CI −2.30至0.59,p=0.2434)。
  • 通气失败分布:2具(18%)用所有气道类型均成功通气,3具(27%)仅能用TI通气,2具(18%)用包括TI在内的任何装置均无法充分通气。

证据类型、等级与局限

  • 证据类型:前瞻性随机交叉尸体研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 尸体模型提示:持续胸外按压下以SGA实施CCSV时,达到pCCSV目标范围的可能性低于TI,且潮气量更低、漏气更多;作者结论强调无论使用何种气道装置CCSV均可能失败,需对呼吸进行密切监测。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: This study aimed to evaluate the efficacy of Chest-Compression-Synchronized-Ventilation (CCSV) using supraglottic airway devices (SGA) compared to tracheal intubation (TI) for ventilation during continuous resuscitation.

METHODS: In this cross-over study, the lungs of adult Thiel-embalmed cadavers were initially recruited using TI. Subsequently, various SGA (Laryngeal-Mask = Ambu®AuraGain™, Laryngeal-Tube = LTS-D®, i-gel-Laryngeal-Mask = I-GEL®) and TI were applied in randomized order during continuous chest compressions. CCSV was delivered with a CCSV-Pressure (pCCSV) = 40 mbar, PEEP = 3 mbar, respiratory-rate (RR) synchronized with the chest compression rate. The primary endpoint was achieving a pCCSV = 40 ± 3 mbar. Secondary endpoints included pCCSV, expiratory tidal (Vte) 1 ml/kgBW and leakage volumes (Vleak). Logistic regression models with random intercepts were used for the primary outcome, and linear mixed models were applied for secondary outcomes.

RESULTS: Eleven cadavers were included. While two(18 %) were successfully ventilated with all airway types, three(27 %) could only be ventilated with an TI. Two cadavers(18 %) could not be sufficiently ventilated with any of the airway devices including TI. When comparing TI and SGA, for TI a greater chance of reaching the target corridor of pCCSV (Odds Ratio(OR) = 1.87; 95 %-Confidence-Interval(95 %CI) = [0.91-3.83]; P = 0.0864) and a higher pCCSV was observed (regression-coefficient(RC) = 2.99 mbar; 95 %CI = [1.63-4.35]; p < 0.0001), along with a higher Vte (RC = 42.42 ml; 95 %CI = [32.07-52.27]; p < 0.0001), and a lower Vleak (RC = -55.03 %; 95 %CI = [-62.92-47.15]; p < 0.0001). In comparisons among the individual SGA, lower pCCSV-values were observed for Ambu®AuraGain™ versus I-GEL® (RC = -2.58 mbar; 95 %CI = [-4.04--1.13]; p = 0.0006), Ambu®AuraGain™ versus LTS-D® (RC = -1.73 mbar; 95 %CI = [-3.18--0.27]; p = 0.0204), and LTS-D® versus I-GEL® (RC = -0.86 mbar; 95 %CI = [-2.30-0.59]; p = 0.2434).

CONCLUSION: SGA were associated with a lower likelihood of reaching the target range of pCCSV, lower Vte, and higher Vleak. Regardless the airway device, CCSV-failure is possible emphasizing the need for vigilant respiratory monitoring.

REGISTRATION: URL: https://www.

CLINICALTRIALS: gov. Unique identifier number: NCT06306898.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Gelashvili T, Brand-Saberi B, Darvishali M, et al. Efficacy of supraglottic airway devices in chest compression synchronized ventilation during continuous resuscitation: a prospective randomized cross-over cadaver study. Resuscitation. 2025. PMID: 40907692. doi:10.1016/j.resuscitation.2025.110795

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。